nach oben

Erschienen in:

19.02.2020 | Acute Coronary Syndrome

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation

verfasst von: Christina Yip, Aruni Seneviratna, Sock-Hwee Tan, Thet Khaing, Siew-Pang Chan, Joshua Loh, Chi-Hang Lee, Adrian F. Low, Chester L. Drum, Sock-Cheng Poh, C. Michael Gibson, E. Magnus Ohman, A. Mark Richards, Mark Y. Chan

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Coronary artery disease is a leading cause of morbidity and mortality worldwide. Despite significant advances in revascularization strategies and antiplatelet therapy with aspirin and/or P2Y₁₂ receptor antagonist, patients with acute coronary syndrome (ACS) continue to be at long-term risk of further cardiovascular events. Besides platelet activation, the role of thrombin generation (TG) in atherothrombotic complications is widely recognized. In this study, we hypothesized that there is an elevation of coagulation activation persists beyond 12 months in patients with ACS and chronic coronary syndrome (CCS) when compared with healthy controls. We measured TG profiles of patients within 72 h after percutaneous coronary intervention, at 6-month, 12-month and 24-month. Our results demonstrated that TG of patients with ACS (n = 114) and CCS (n = 40) were persistently elevated when compared to healthy individuals (n = 50) in peak thrombin (ACS 273.1 nM vs CCS 287.3 nM vs healthy 234.3 nM) and velocity index (ACS 110.2 nM/min vs CCS 111.0 nM/min vs healthy 72.9 nM/min) at 24-month of follow-up. Our results suggest a rationale for addition of anticoagulation to antiplatelet therapy in preventing long-term ischemic events after ACS. Further research could clarify whether the use of TG parameters to enable risk stratification of patients at heightened long-term procoagulant risk who may benefit most from dual pathway inhibition.

Ben-Dor I, Kleiman NS, Lev E (2009) Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 104(2):227–233. https://doi.org/10.1016/j.amjcard.2009.03.022 CrossRefPubMed

Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD (2011) Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 13(2):148–153. https://doi.org/10.1093/eurjhf/hfq194 CrossRefPubMed

Abu-Assi E, Lopez-Lopez A, Gonzalez-Salvado V, Redondo-Dieguez A, Pena-Gil C, Bouzas-Cruz N, Raposeiras-Roubin S, Riziq-Yousef Abumuaileq R, Garcia-Acuna JM, Gonzalez-Juanatey JR (2016) The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed) 69(1):11–18. https://doi.org/10.1016/j.rec.2015.06.015 CrossRef

Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M (2015) Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 36(19):1163–1170. https://doi.org/10.1093/eurheartj/ehu505 CrossRefPubMed

Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, Bertocchi F, Rosenberg RD, Mannucci PM (2003) Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102(8):2731–2735. https://doi.org/10.1182/blood-2002-03-0954 CrossRefPubMed

Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K, Mann KG (2008) Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 6(1):104–110. https://doi.org/10.1111/j.1538-7836.2007.02799.x CrossRefPubMed

Loeffen R, van Oerle R, Leers MP, Kragten JA, Crijns H, Spronk HM, Ten Cate H (2016) Factor XIa and thrombin generation are elevated in patients with acute coronary syndrome and predict recurrent cardiovascular events. PLoS ONE 11(7):e0158355. https://doi.org/10.1371/journal.pone.0158355 CrossRefPubMedPubMedCentral

Ten Cate H, Hemker HC (2016) Thrombin generation and atherothrombosis: what does the evidence indicate? J Am Heart Assoc. https://doi.org/10.1161/jaha.116.003553 CrossRefPubMedPubMedCentral

Smid M, Dielis AWJH, Winkens M, Spronk HMH, Van Oerle R, Hamulyák K, Prins MH, Rosing J, Waltenberger JL, Ten Cate H (2011) Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 9(3):450–456. https://doi.org/10.1111/j.1538-7836.2010.04162.x CrossRefPubMed

10.

Weitz JI (2014) Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost 112(5):924–931. https://doi.org/10.1160/th14-03-0265 CrossRefPubMed

11.

Koren O, Azaizah M, Rozner E, Elias M, Turgeman Y (2019) Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-019-01996-6 CrossRef

12.

Posma JJ, Posthuma JJ, Spronk HM (2016) Coagulation and non-coagulation effects of thrombin. J Thromb Haemost 14(10):1908–1916. https://doi.org/10.1111/jth.13441 CrossRefPubMed

13.

Mammadova-Bach E, Mauler M, Braun A, Duerschmied D (2018) Autocrine and paracrine regulatory functions of platelet serotonin. Platelets 29(6):541–548. https://doi.org/10.1080/09537104.2018.1478072 CrossRefPubMed

14.

Walsh TG, Poole AW (2018) Do platelets promote cardiac recovery after myocardial infarction: roles beyond occlusive ischemic damage. Am J Physiol Heart Circ Physiol 314(5):H1043–H1048. https://doi.org/10.1152/ajpheart.00134.2018 CrossRefPubMedPubMedCentral

15.

Orbe J, Zudaire M, Serrano R, Coma-Canella I, Martinez de Sizarrondo S, Rodriguez JA, Paramo JA (2008) Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 99(2):382–387. https://doi.org/10.1160/th07-07-0443 CrossRefPubMed

16.

Attanasio M, Marcucci R, Gori AM, Paniccia R, Valente S, Balzi D, Barchielli A, Carrabba N, Valenti R, Antoniucci D, Abbate R, Gensini GF (2016) Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thromb Res 147:52–57. https://doi.org/10.1016/j.thromres.2016.09.020 CrossRefPubMed

17.

Berezovskaya G, Smirnova O, Malev E, Khromov-Borisov N, Klokova E, Karpenko M, Papayan L, Petrishchev N (2017) Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention. Platelets. https://doi.org/10.1080/09537104.2017.1294680 CrossRefPubMed

18.

Schneider JG, Isermann B, Kleber ME, Wang H, Boehm BO, Grammer TB, Prueller F, Nawroth PP, Maerz W (2014) Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Int J Cardiol 176(1):139–144. https://doi.org/10.1016/j.ijcard.2014.07.026 CrossRefPubMed

19.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60(16):1581–1598. https://doi.org/10.1016/j.jacc.2012.08.001 CrossRefPubMed

20.

Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33(1):4–15. https://doi.org/10.1159/000071636 CrossRefPubMed

21.

Hemker HC, Wielders S, Kessels H, Beguin S (1993) Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 70(4):617–624CrossRefPubMed

22.

Tripodi A (2016) Thrombin generation assay and its application in the clinical laboratory. Clin Chem 62(5):699–707. https://doi.org/10.1373/clinchem.2015.248625 CrossRefPubMed

23.

van Veen JJ, Gatt A, Makris M (2008) Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142(6):889–903. https://doi.org/10.1111/j.1365-2141.2008.07267.x CrossRefPubMed

24.

Dielis AWJH, Castoldi E, Spronk HMH, Van Oerle R, Hamulyák K, Ten Cate H, Rosing J (2008) Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 6(1):125–131. https://doi.org/10.1111/j.1538-7836.2007.02824.x CrossRefPubMed

25.

Lipets EN, Ataullakhanov FI (2015) Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J 13(1):4. https://doi.org/10.1186/s12959-015-0038-0 CrossRefPubMedPubMedCentral

26.

Westland J (2012) Erratum to “Lower bounds on sample size in structural equation modeling” [Electron. Commerce Res. Appl. 9(6) (2010) 476–487]. Electron Commerce Res Appl 11:445. https://doi.org/10.1016/j.elerap.2012.06.001 CrossRef

27.

Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C, Goette A (2013) Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol 718(1–3):114–123. https://doi.org/10.1016/j.ejphar.2013.09.006 CrossRefPubMed

28.

Sakamoto A, Jinnouchi H, Torii S, Virmani R, Finn AV (2018) Understanding the impact of stent and scaffold material and strut design on coronary artery thrombosis from the basic and clinical points of view. Bioengineering (Basel). https://doi.org/10.3390/bioengineering5030071 CrossRefPubMedCentral

29.

Bae JS, Yang L, Rezaie AR (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 104(8):2867–2872. https://doi.org/10.1073/pnas.0611493104 CrossRefPubMedPubMedCentral

30.

Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, O’Reilly LA, Henley KJ, Ono A, Hsiao S, Willcox A, Roberts AW, Huang DC, Salem HH, Kile BT, Jackson SP (2009) Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 114(3):663–666. https://doi.org/10.1182/blood-2009-01-200345 CrossRefPubMed

31.

Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116(7):745–754. https://doi.org/10.1161/circulationaha.106.686048 CrossRefPubMed

32.

Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW (2005) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45(6):947–953. https://doi.org/10.1016/j.jacc.2004.09.079 CrossRefPubMed

33.

Loeffen R, Godschalk TC, van Oerle R, Spronk HM, Hackeng CM, ten Berg JM, ten Cate H (2015) The hypercoagulable profile of patients with stent thrombosis. Heart 101(14):1126–1132. https://doi.org/10.1136/heartjnl-2014-306685 CrossRefPubMed

34.

Cohen M, Iyer D (2014) The “Dual-Pathway” strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 Trial. Cardiovasc Ther 32(5):224–232. https://doi.org/10.1111/1755-5922.12083 CrossRefPubMed

35.

Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, Jain P, Plotnikov A, Burton P, Gibson CM (2017) Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. https://doi.org/10.1177/2048872617745003 CrossRefPubMed

36.

Sumaya W, Geisler T, Kristensen SD, Storey RF (2019) Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease? Thromb Haemost. https://doi.org/10.1055/s-0039-1679903 CrossRefPubMed

37.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330. https://doi.org/10.1056/NEJMoa1709118 CrossRefPubMed

38.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B (2018) Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 379(14):1332–1342. https://doi.org/10.1056/NEJMoa1808848 CrossRefPubMed

39.

Elias A, Rock W, Odetalla A, Ron G, Schwartz N, Saliba W, Elias M (2019) Enhanced thrombin generation in patients with arterial hypertension. Thromb Res 174:121–128. https://doi.org/10.1016/j.thromres.2018.11.027 CrossRefPubMed

40.

Hansen CH, Ritschel V, Halvorsen S, Andersen GO, Bjornerheim R, Eritsland J, Arnesen H, Seljeflot I (2015) Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. Thromb J 13:31. https://doi.org/10.1186/s12959-015-0061-1 CrossRefPubMedPubMedCentral

41.

Picariello C, Lazzeri C, Attana P, Chiostri M, Gensini GF, Valente S (2011) The impact of hypertension on patients with acute coronary syndromes. Int J Hypertens 2011:563657. https://doi.org/10.4061/2011/563657 CrossRefPubMedPubMedCentral

42.

Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, Mannucci PM (2011) Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31(2):165–172. https://doi.org/10.1007/s11239-010-0506-0 CrossRefPubMed

43.

Bell EJ, Folsom AR, Lutsey PL, Selvin E, Zakai NA, Cushman M, Alonso A (2016) Diabetes mellitus and venous thromboembolism: a systematic review and meta-analysis. Diabetes Res Clin Pract 111:10–18. https://doi.org/10.1016/j.diabres.2015.10.019 CrossRefPubMed

44.

Goel K, Lennon RJ, Tilbury RT, Squires RW, Thomas RJ (2011) Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 123(21):2344–2352. https://doi.org/10.1161/circulationaha.110.983536 CrossRefPubMed

45.

Altman R, Scazziota A, De Lourdes HM, Gonzalez C (2006) Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 4(9):2022–2027. https://doi.org/10.1111/j.1538-7836.2006.02088.x CrossRefPubMed

46.

Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, Hatada T, Ishikura K, Yamada N, Sudo A, Uchida A, Nobori T (2008) Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost 14(3):279–285. https://doi.org/10.1177/1076029607309176 CrossRefPubMed

47.

Kopeć G, Moertl D, Steiner S, Stępień E, Mikołajczyk T, Podolec J, Waligóra M, Stępniewski J, Tomkiewicz-Pająk L, Guzik T, Podolec P (2013) Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension. PLoS ONE 8(12):e82628. https://doi.org/10.1371/journal.pone.0082628 CrossRefPubMedPubMedCentral

48.

Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90(1):61–68CrossRefPubMed

49.

Artang R, Anderson M, Riley P, Nielsen JD (2017) Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res Pract Thromb Haemost 1(2):194–201. https://doi.org/10.1002/rth2.12044 CrossRefPubMedPubMedCentral

50.

Wexels F, Dahl OE, Pripp AH, Seljeflot I (2017) Thrombin generation in patients with suspected venous thromboembolism. Clin Appl Thromb Hemost 23(5):416–421. https://doi.org/10.1177/1076029617700999 CrossRefPubMed

Titel: Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation
verfasst von: Christina Yip
Aruni Seneviratna
Sock-Hwee Tan
Thet Khaing
Siew-Pang Chan
Joshua Loh
Chi-Hang Lee
Adrian F. Low
Chester L. Drum
Sock-Cheng Poh
C. Michael Gibson
E. Magnus Ohman
A. Mark Richards
Mark Y. Chan
Publikationsdatum: 19.02.2020
Verlag: Springer US
Schlagwörter: Acute Coronary Syndrome
Arterial Diseases
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02066-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials

Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes

Baseline thrombocytopenia in women with coronary heart disease increases incident acute coronary syndrome: insights from national inpatient database

Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients

Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia

Correction to: Heparin resistance in COVID‑19 patients in the intensive care unit

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin